I just came across this:
Brokerages Set Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Target Price at $14.25
Posted on December 10, 2015 by Tim Parker in Consensus Rating Articles, Investing
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has earned an average rating of “Buy” from the six ratings firms that are currently covering the firm, Analyst Ratings.Net reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $14.25.
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.5593 on Monday. The company has a 50-day moving average of $3.66 and a 200-day moving average of $4.05. Threshold Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $5.28. The company’s market capitalization is $39.97 million.
Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings data on Monday, November 2nd. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. The business earned $3.70 million during the quarter, compared to analysts’ expectations of $3.69 million. Equities analysts expect that Threshold Pharmaceuticals will post ($0.52) EPS for the current fiscal year.
A number of equities analysts recently commented on the stock. Piper Jaffray cut shares of Threshold Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. Cowen and Company cut shares of Threshold Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday. Stifel Nicolaus cut shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Threshold Pharmaceuticals in a research note on Monday, October 5th. Finally, RBC Capital reaffirmed a “buy” rating on shares of Threshold Pharmaceuticals in a research note on Tuesday, September 15th.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Threshold’s investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Threshold’s [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.
AI
